Navigation Links
Novel discovery by NUS scientists paves the way for more effective treatment of cancers
Date:5/21/2012

A team of scientists from the National University of Singapore's (NUS) Department of Biological Sciences and Mechanobiology Institute have discovered how a drug-led compound a compound that is undergoing preclinical trials as a potential drug can deprive cancer cells of energy and stop them from growing into a tumour. This drug-led compound is named BPTES.

This is the first time a research group has provided evidence showing how a drug-lead compound suppresses tumour formation.

Building on the new findings, the NUS team also derived positive results for a novel dual-drug treatment regime involving BPTES that kills kidney and breast cancer cells more effectively.

The team led by Associate Professor Low Boon Chuan and Associate Professor Jayaraman Sivaraman first published their findings in the journal of Proceedings of the National Academy of Sciences (PNAS) on 26 April 2012.

Killing cancer cells by 'starving' them of energy

Classic experiments in cancer biology have demonstrated that cancer cells feed off the breakdown of the amino acid glutamine to gain energy and grow into a tumour. While it is known that human glutaminase is the first enzyme in catalysing this series of biochemical reactions, little is known about how its activity is controlled, and how it can be manipulated.

The NUS research team has successfully identified the mechanism in which the BPTES that can bind and inhibit glutaminase, can effectively starve the cancer cells of their energy source, and hence, could potentially prevent tumour growth.

In addition, the team has also found that the glutaminase activity can be activated upon the addition of phosphate by epidermal growth factor signaling a pathway that controls cancer cells proliferation. By using another inhibitor to block the kinase Mek2 within this cancer-causing pathway, coupled with the use of BPTES, the combined therapeutic effect is more potent and less toxic. This raises the hope of offering a new dual-drug cancer treatment regime for cancers such as lymphoma, prostate, glioblastoma, breast and kidney cancer cells that is more effective and with fewer side-effects.

The Next Step

Armed with structural insights into the binding and signaling pathway that activates glutaminase, the NUS research team is conducting more studies to determine whether a combination of drugs would be even more effective in inhibiting glutaminase activity and hence, tumour formation.

Using the knowledge that they gained through their current studies, the research team will also look into optimising the tumour suppression property of BPTES to increase its efficiency and lower its side-effects.


'/>"/>
Contact: Carolyn Fong
carolyn@nus.edu.sg
65-651-65399
National University of Singapore
Source:Eurekalert

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... compared the implantation and pregnancy rates in frozen and fresh in vitro ... of progesterone and maternal age to IVF success. , After comparing the results ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... DALLAS , Oct. 10, 2017 International research firm ... IoT Strategy, will speak at the TMA 2017 Annual Meeting , ... key trends in the residential home security market and how smart safety ... ... "The ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
Breaking Biology Technology: